作者: Vinoth Kumar Ponnusamy , Arivalagan Pugazhendhi , Arivalagan Pugazhendhi , Kathirvel Brindhadevi , V. Bharath Kumar
DOI: 10.1016/J.PROCBIO.2021.02.004
关键词: Review article 、 Clinical trial 、 non-small cell lung cancer (NSCLC) 、 Medicine 、 Internal medicine 、 High doses 、 Cancer 、 Oncology 、 Phytochemical 、 Non small cell 、 Clinical Practice
摘要: Abstract Over the past few decades, many of phytochemicals have been shown to possess extraordinary anticancer effects, clinical tested, approved as drugs, and currently in use. A considerable number either a single-agent or combined with existing drugs at pre-clinical levels evaluated date. However, trials on phytochemical evaluations against world's top-ranked cancer, NSCLC, was found be very little. Some that showed significant activity NSCLC vitro and/or vivo preclinical are highlighted this review article. There several impediments such poor solubility, bioavailability, low stability, requirement high doses, safety toxicity limits wide-spread use oncology. Nanotherapeutic systems can help overcome aforementioned issues wide open gates focus phyto-oncotherapy, particular NSCLC. The current aims summarize importance agents, special mention nano-formulations treat non-small cell lung cancer (NSCLC).